Dec 07 2020 Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder View
Oct 27 2020 Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones View
Jun 23 2020 Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms View
Jun 09 2020 Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference View
May 27 2020 Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder View
May 26 2020 Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations View
Apr 28 2020 Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs View
